Get started
Author

Maja Bürdek

Observed names: Bürdek, Maja, M. Bürdek, Maja Buerdek
Institution: Medigene (Germany)
ORCID: 0000-0002-1819-2122
Observed ORCID: 0000-0002-1819-2122
OpenAlex ID: A5082770948
Recent advances on the role of tumor exosomes in immunosuppression and disease progression
2012 · Paola Filipazzi, Maja Bürdek, et al. · Seminars in Cancer Biology · 289
PDF
TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2016 · Licia Rivoltini, Claudia Chiodoni, et al. · Clinical Cancer Research · 194
PDF
Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
2010 · Stefani Spranger, Miran Javorovic, et al. · The Journal of Immunology · 86
Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
2019 · Akiko Arakawa, Sigrid Vollmer, et al. · Frontiers in Immunology · 76
PDF
Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation
2010 · Maja Bürdek, Stefani Spranger, et al. · Journal of Translational Medicine · 48
PDF
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
2022 · Nadja Sailer, Ina Fetzer, et al. · Cancers · 38
PDF
Characterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid Malignancies
2025 · Maja Bürdek, Petra U. Prinz, et al. · Cancers · 2
PDF
Preclinical Development of Costimulatory Switch Protein (CSP)-Armored NY-ESO-1/LAGE-1a-Specific TCR-T Cells for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors
2025 · Maja Bürdek, Petra U. Prinz, et al. · International Journal of Translational Medicine · 1
PDF
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms
2025 · Simone Thomas, Martin Wermke, et al. · Cancers · 1
PDF
2249P Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
2023 · K. Crame, G. Longinotti, et al. · Annals of Oncology · 1
PDF
Abstract 4057: T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors
2023 · Andrea Coluccio, Stefanie Tippmer, et al. · Cancer Research · 1
1043P Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
2024 · K. Crame, D. Alterauge, et al. · Annals of Oncology
PDF
Abstract 12: TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB
2024 · Maja Buerdek, Petra U. Prinz, et al. · Cancer Research
Supplementary Materials and Methods from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure S2 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure S4 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure S3 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure S1 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure Legends from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Data from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
Supplementary Figure S4 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2023 · Licia Rivoltini, Claudia Chiodoni, et al.
PDF
1007P T-cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors
2021 · M. Bürdek, I. Fetzer, et al. · Annals of Oncology
Abstract 1521: Combining a PRAME-specific TCR showing potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile with a PD1-41BB switch receptor results in highly efficient T cells
2021 · Ina Fetzer, Nadja Sailer, et al. · Cancer Research
The T cell therapy field faces preclinical and translational R&D challenges as it targets more complex diseases
2021 · Gary Waanders, Silke Raffegerst, et al. · Cell and Gene Therapy Insights
Abstract 3231: The chimeric co-stimulatory receptor PD1-41BB enhances the function of T cell receptor (TCR)-modified T cells targeting solid tumors
2020 · Nadja Sailer, Melanie Salvermoser, et al. · Cancer Research
Works count: 29
Citation count: 737
H-index: 6
I10-index: 6
Year
Topic
Type